



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 05 August 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: OUTCOME OF THE BOARD MEETING

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., 05 August 2022, inter alia, duly approved/took on record the following:

- Unaudited Standalone Financial Results and Unaudited Consolidated Financial Results for the quarter ended 30 June 2022;
- Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023;
- Further, as Communicated in our intimation letter dated 02 August 2022, the record date for determining the eligibility of shareholders for the payment of the interim dividend has been fixed as 16 August 2022. The payment of interim dividend would be made to the eligible shareholders on or before 04 September 2022.

The Board Meeting commenced at 11:00 A.M. and concluded at 12:35 P.M.

Kindly take the above information on your records.

Thanking You,

Yours faithfully,

Eris Lifesciences Limited



Milind Talegaonkar
Company Secretary and Compliance Officer

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867